Q4 2024 BioLife Solutions Inc Earnings Call Transcript
Key Points
- BioLife Solutions Inc (BLFS) achieved five consecutive quarters of growth in cell processing revenue, exceeding the high end of their full-year guidance.
- The company successfully divested non-core product lines, resulting in a stronger and cleaner balance sheet with a doubled cash balance of $109 million by the end of 2024.
- GAAP gross margin improved significantly from 31% in 2023 to 62% in 2024, generating $51 million in gross margin dollars.
- Adjusted EBITDA turned positive in 2024, reaching $16 million or 19% of revenue, compared to a negative $5 million in 2023.
- BioLife Solutions Inc (BLFS) anticipates 16% to 20% revenue growth in 2025, driven primarily by their cell processing platform, with expected growth in adjusted EBITDA margin.
- Total revenue in 2024 decreased to $82 million from $143 million in 2023 due to divestitures.
- EVO and SAW platform revenue for Q4 2024 decreased by 8% compared to the same period in 2023.
- GAAP operating expenses for Q4 2024 increased slightly to $24.8 million from $24.4 million in Q4 2023.
- The company faces competition from home-brew formulations in the media market and established products like cryobags in the CryoCase market.
- R&D expenses are expected to increase in 2025, which may offset some of the anticipated revenue growth.
Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Q4 2024 shareholder and analyst conference call. (Operator Instructions). As a reminder, today's call is being recorded. I would now like to turn the conference call over to Troy Wichterman, Chief Financial Officer of BioLife Solutions.
Thank you, operator. Good morning, everyone, and thank you for joining the BioLife Solutions 2024 fourth-quarter earnings conference call. On this call, we will cover business highlights, financial performance for the quarter and full year 2024 and present 2025 revenue guidance. Earlier today, we issued a press release announcing our financial results and our operational highlights for the fourth quarter and full year of 2024 and 2025 revenue guidance, which is available at biolifesolutions.com.
As a reminder, during this call, we will make forward-looking statements. These statements are subject to risks and uncertainties that can be found in our SEC
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
